Skip to main content

autologous anti-claudin18.2 car t-cells lb1908

Generic: Autologous Anti-Claudin18.2 CAR T-cells LB1908

autologous anti-claudin18.2 car t-cells lb1908: 1 clinical trial tracked.

autologous anti-claudin18.2 car t-cells lb1908 evidence translation

What we can confirm

1 tracked trial

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about autologous anti-claudin18.2 car t-cells lb1908, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (1)

A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

NCT05539430Registry updated 2026-09-02·Phase 1
Active, not recruiting

Primary endpoint: To characterize the safety and tolerability of LB1908 and determine the optimal dose or recommended dose for expansion (RDE)

Interventionalopen56 targetStarted 2023-04Completion 2027-129 sites · United StatesLegend Biotech USA Inc